checkAd

ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research

Westport, CT, April 23, 2020 (GLOBE NEWSWIRE) --

  • Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in pre-clinical testing.
  • Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch

BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, The IMPDH inhibitor merimepodib has similar antiviral activity against SARS-CoV-2 replication in vitro to the adenosine analogue remdesivir” was accepted by F1000 Research, an  online peer-reviewed life sciences journal publishing program in biology and medicine.

This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author.

The article highlights emerging pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. The work was started with Trek Therapeutics and after merimepodib was acquired by ViralClear has been continued by ViralClear.

“The concentrations of merimepodib used in the cell culture studies described in this article are achievable in humans by our oral solution formulation,” said Dr. Zeldis, Executive Chair and Founder of ViralClear Pharmaceuticals, Inc. “We are now exploring whether remdesivir and merimepodib are synergistic in this in vitro model.  We look forward to starting our first clinical trial in COVID-19 patients upon receiving FDA clearance to commence with the proposed phase 2 trial.”

Vero cells in tissue culture were pre-treated with two concentrations (2.5 and 5 µM) of either merimepodib or remdesivir for 4 hours before the SARS-CoV-2 coronavirus was added.  The amount of virus released to the media was measured at baseline and 16 hours and 24 hours after infection.  At 16 hours, a significant reduction in viral production was observed for both concentrations of merimepodib (1.9 log decrease in titer, p = 0.003 and 2.1 log decrease in titer, p = 0.001) but only at the higher concentration of remdesivir (1 log decrease in titer, p = 0.103 and 2.1-log decrease in titer, p = 0.001).  At 24 hours both concentrations of both drugs significantly reduced viral production; however, 2.5 µM remdesivir reduced viral titer by 1.5 logs (p = 0.002) as compared to a decrease of 3.9 logs for 5 µM remdesivir (p < 0.001), whereas 2.5 and 2.7 log reductions (p = 0.001 and p < 0.001, respectively) were observed for the 2.5 and 5 µM concentrations of merimepodib. 

Seite 1 von 2




0 Kommentare
Nachrichtenquelle: globenewswire
 |  260   |   |   

Schreibe Deinen Kommentar

Disclaimer

ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research Westport, CT, April 23, 2020 (GLOBE NEWSWIRE) - Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in pre-clinical testing.Article highlights recent work done …

Nachrichten des Autors

128 Leser
100 Leser
720 Leser
624 Leser
512 Leser
508 Leser
508 Leser
484 Leser
468 Leser
464 Leser
456 Leser
452 Leser
1676 Leser
1124 Leser
1120 Leser
956 Leser
840 Leser
828 Leser
820 Leser
804 Leser
800 Leser
752 Leser
10577 Leser
4428 Leser
3488 Leser
2744 Leser
2294 Leser
2246 Leser
2077 Leser
2052 Leser
2037 Leser
1943 Leser